'DURVIT': Single low-dose DURValumab IntraTumorally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Durvalumab (Primary)
- Indications Cervical cancer
- Focus Adverse reactions
- Acronyms DURVIT
- 10 Dec 2017 Planned End Date changed from 1 Apr 2018 to 1 Dec 2019.
- 10 Dec 2017 Planned initiation date changed from 1 Apr 2016 to 1 Dec 2017.
- 13 Dec 2016 New trial record